Early postoperative plasma circulating tumour DNA for molecular residue disease detection and recurrence risk evaluation in surgical non‐small cell lung cancer

Ähnliche Einträge

• Comprehensive genomic analysis of molecular residual disease based on circulating tumour DNA in postoperative patients with colorectal cancer
  von: Qingqi Hong, et al.
  Veröffentlicht: (2024)
• Pathologic nodal metastasis assessment using tumour‐derived molecular features in patients with lung adenocarcinoma
  von: Shijie Wang, et al.
  Veröffentlicht: (2024)
• Longitudinal circulating tumour DNA dynamics predict failure patterns and efficacy of consolidation immunotherapy after chemoradiotherapy in locally advanced non‐small‐cell lung cancer
  von: Yu Wang, et al.
  Veröffentlicht: (2024)
• Restoring expression of tumour suppressor PTEN by engineered circular RNA‐enhanced Osimertinib sensitivity in non‐small cell lung cancer
  von: Haoran Li, et al.
  Veröffentlicht: (2024)
• Single‐cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non‐small‐cell lung cancer
  von: Xiaoshen Zhang, et al.
  Veröffentlicht: (2024)